福光股份(688010.SH):部分募投項目增加實施主體、實施地點及延長建設期
格隆匯9月29日丨福光股份(688010.SH)公佈,受國內新型冠狀病毒肺炎疫情影響,“全光譜精密鏡頭智能製造基地建設項目(一期)”的廠房裝修施工進展滯後。受國際新型冠狀病毒肺炎疫情嚴峻形勢影響,“全光譜精密鏡頭智能製造基地建設項目(一期)”和“稜鏡冷加工產業化建設項目”部分進口設備的選型、採購進度有所滯後。
公司擬增加福建福光股份有限公司作為募投項目“全光譜精密鏡頭智能製造基地建設項目(一期)”的實施主體,對應新增的實施地點為福建省福州市馬尾區江濱東大道158號,並將建設期延長至2021年9月。
公司將募投項目“稜鏡冷加工產業化建設項目”的建設期延長至2021年4月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.